NGL Fine Chem Ltd

NGL Fine Chem Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

NGL Fine Chem Ltd

₹ 2,698 -4.33%
27 May - close price
nglfinechem.com BSE: 524774 NSE: NGLFINE
About

Incorporated in 1981, NGL Fine-Chem Ltd is a manufacturer and exporter of pharmaceuticals and intermediates for usage in veterinary and human health.[1]

Key Points

Business Overview:[1][2]
NGLFCL primarily manufactures veterinary pharmaceutical APIs and intermediates, catering to the antiprotozoal and anthelmintic therapeutic segments. Its products are used in the animal healthcare industry.

Product Profile:[3][4]
It has ~39 APIs (37 Veterinary APIs, 2 Human APIs), ~4 Intermediates, and ~12 finished dosage forms, etc., in the categories of Anthelmintics, Antiprotozoals, Ectoparasiticides, and Phosphorus Supplements

Website BSE NSE
  • Market Cap ₹ 1,667 Cr.
  • Current Price ₹ 2,698
  • High / Low ₹ 3,005 / 980
  • Stock P/E 34.6
  • Book Value ₹ 533
  • Dividend Yield 0.06 %
  • ROCE 17.0 %
  • ROE 15.7 %
  • Face Value ₹ 5.00
Edit ratios

Pros

  • Company is expected to give good quarter

Cons

  • Company has a low return on equity of 13.5% over last 3 years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
75 71 80 88 100 91 93 89 95 104 120 128 149
61 61 66 74 84 81 82 84 89 93 103 105 128
Operating Profit 14 10 14 14 16 9 12 5 6 11 17 22 21
OPM % 19% 14% 17% 16% 16% 10% 12% 6% 7% 11% 14% 18% 14%
1 3 3 4 4 6 5 -0 -1 6 2 5 2
Interest 0 0 0 0 0 0 0 1 1 1 1 1 1
Depreciation 3 3 3 3 3 3 3 3 3 4 5 5 5
Profit before tax 12 10 14 14 16 12 13 1 1 12 13 21 18
Tax % 23% 16% 25% 30% 23% 22% 26% -1% 49% 22% 26% 24% 24%
9 9 10 10 12 9 10 1 1 9 10 16 13
EPS in Rs 15.09 13.77 16.96 16.24 19.94 14.92 15.88 2.07 0.87 14.96 15.59 25.40 21.84
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
153 152 258 318 278 339 368 501
121 130 178 249 243 285 333 428
Operating Profit 32 22 80 68 35 54 35 73
OPM % 21% 14% 31% 21% 13% 16% 9% 15%
4 1 8 11 6 14 9 15
Interest 3 3 2 2 2 2 3 4
Depreciation 6 8 8 10 11 12 12 20
Profit before tax 28 12 78 67 27 54 28 63
Tax % 27% 31% 27% 25% 25% 24% 24% 24%
20 8 57 50 20 41 21 48
EPS in Rs 32.58 13.50 91.81 80.77 33.18 66.88 34.19 77.91
Dividend Payout % 5% 13% 2% 2% 5% 3% 5% 0%
Compounded Sales Growth
10 Years: %
5 Years: 14%
3 Years: 22%
TTM: 36%
Compounded Profit Growth
10 Years: %
5 Years: -3%
3 Years: 33%
TTM: 128%
Stock Price CAGR
10 Years: 27%
5 Years: 8%
3 Years: 22%
1 Year: 132%
Return on Equity
10 Years: %
5 Years: 15%
3 Years: 13%
Last Year: 16%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity Capital 3 3 3 3 3 3 3 3
Reserves 89 96 151 200 219 260 279 326
27 28 16 30 32 34 77 108
23 26 36 44 32 59 74 108
Total Liabilities 142 154 207 277 287 356 433 546
61 68 64 89 88 86 143 164
CWIP 0 0 12 6 26 46 50 95
Investments 9 11 29 29 39 54 60 39
73 75 102 153 133 171 181 247
Total Assets 142 154 207 277 287 356 433 546

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
9 20 27 14 35 20 36 43
-10 -20 -25 -14 -27 -27 -35 -71
0 -1 -1 -1 -1 -1 -1 30
Net Cash Flow -1 -0 2 -1 7 -7 0 2
Free Cash Flow -6 6 10 -15 5 -8 -38 -43
CFO/OP 50% 110% 60% 45% 121% 62% 122% 81%

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 79 63 53 74 86 97 81 95
Inventory Days 106 155 132 137 69 98 101 107
Days Payable 92 116 103 91 63 112 113 98
Cash Conversion Cycle 93 102 82 120 93 83 68 104
Working Capital Days 70 58 69 90 68 76 50 88
ROCE % 14% 54% 34% 12% 20% 9% 17%

Insights

In beta
Mar 2019 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Animal API Revenue Contribution
%

Log in to view insights

Please log in to see hidden values.

Login
Number of APIs (Commercial)
Count
R&D Expenditure as % of Turnover
%
Number of Customers
Count
Outsourced Production Share
%
Reactor Capacity
kl
Top 10 Products Revenue Contribution
%
Capacity Utilization
%
R&D Expenditure (Percentage of Turnover)
% ・Standalone data

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
73.53% 73.06% 73.06% 72.74% 72.74% 72.74% 72.74% 72.74% 72.74% 72.74% 72.74% 72.73%
0.00% 0.02% 0.04% 0.10% 0.03% 0.02% 0.05% 0.00% 0.00% 0.00% 0.00% 0.03%
0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
26.46% 26.93% 26.91% 27.16% 27.24% 27.25% 27.23% 27.26% 27.26% 27.26% 27.26% 27.23%
No. of Shareholders 17,06617,62316,41015,04114,60814,57514,11014,38614,01013,38712,83412,516

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls